Glaukos (GKOS) Q3 2026 Earnings Call Transcript

Glaukos reported Q3 2026 net sales of $211 million, up 58% year over year, and non-GAAP diluted EPS of $0.47 versus a loss of $0.16 a year earlier. It raised 2026 sales guidance to $775 million–$785 million from $680 million–$700 million and introduced preliminary 2027 revenue guidance of $1 billion, while non-GAAP gross margin expanded to 87.7%. Growth was driven by iDose TR sales of approximately $76 million and Epioxa sales of approximately $53 million; management noted that proposed Medicare local coverage determinations could affect iDose reimbursement and adoption.

Analysis

The key underwriting question is whether Glaukos can convert broad access into repeat treatment volume—not whether it can open sites. For Epioxa, payer pathways and installed treatment capacity are inputs; prior-authorization duration, approvals, and treated eyes are the conversion metrics. A growing site network without faster reimbursement throughput could leave revenue well short of the launch narrative. Also distinguish new keratoconus patients from substitution of legacy Photrexa use: market expansion, not product migration alone, is needed to support a durable growth multiple.

For iDose, Medicare Advantage and commercial growth may cushion exposure to a restrictive Medicare fee-for-service LCD, but could also make utilization more dependent on payer and procedure mix. The Phase IV cataract data helps the clinical case, yet it may not change a coverage decision already under review. That creates a binary near-term catalyst with potentially uneven effects across physician practices.

The reported margin improvement should not be capitalized as a steady-state earnings run rate: mix is improving, while commercialization and R&D spending are still scaling, and retinal programs carry substantial, long-dated investment requirements. Over 6–18 months, screening and referral infrastructure could enlarge the keratoconus market; near term, execution and reimbursement matter more than pipeline optionality. With no valuation or consensus data supplied, the strong operating signal alone does not establish that the stock is cheap.

Key Decisions for Investors

• Avoid chasing the earnings reaction without checking the opening move against valuation and expectations. For an event-driven long, wait for the first few sessions to establish whether the post-print gain holds, then use a starter position rather than underwriting the preliminary 2027 target as guaranteed.
• Treat the iDose LCD as the principal near-term risk catalyst. Reassess exposure on a final coverage determination; a materially restrictive policy or subsequent evidence of weaker iDose utilization would falsify the cushion thesis and warrant reducing the long.
• Track Epioxa conversion, not just access: request updates on treated eyes, prior-authorization approval and turnaround, buy-and-bill versus specialty-pharmacy mix, and repeat utilization. Slowing conversion despite expanding sites would challenge the launch thesis; faster throughput and evidence of incremental patients would strengthen it.
• Do not assign substantial near-term value to retinal pipeline assets based on commercial-launch cash generation alone. Monitor R&D and operating-expense growth against revenue leverage; persistent expense growth without sustained gross-profit conversion would weaken the margin-expansion case.